Pathology of Renal Matrix Metabolism
Pathology of Renal Matrix Metabolism
批准号:
7192529
负责人:
DAVID H LOVETT
金额:
$32.84万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-09-30 至 2009-12-31
关键词:
AtrophicAttentionComplexConditionDevelopmentDiseaseE-CadherinEndopeptidasesEnvironmental Risk FactorEpithelialEpithelial CellsEtiologyEventFOS geneFamilyFibroblastsFibrosisGelatinase AGene Expression RegulationGenerationsGenesGenetic TranscriptionGenomeIn VitroInterruptionKidneyKidney DiseasesLaboratoriesMMP14 geneMaintenanceMatrix MetalloproteinasesMediator of activation proteinMesenchymalMetabolismMicroarray AnalysisModelingNumbersPathologyPathway interactionsPeptide HydrolasesPhenotypePhosphotransferasesPopulationProcessProximal Kidney TubulesRangeReceptor Protein-Tyrosine KinasesResearch DesignRoleSeriesSignal TransductionSourceTestingTranscription Factor AP-1Transforming Growth Factor betaTransgenic OrganismsTubular formationbasebeta catenincohortcytokineepithelial to mesenchymal transitionhuman MMP14 proteinin vitro Modelin vivointerstitialmembernovel therapeuticstherapeutic targettranscription factor
中文摘要
描述(由申请人提供):间质纤维化和肾小管萎缩是所有形式进行性肾纤维化的标志。在过去的十年中,该实验室一直专注于特异性(MMP-2和MT1-MMP)在这一过程中的作用。MMP-2与MT1-MMP结合,足以诱导极化上皮细胞向成纤维细胞表型转化,这一过程称为上皮间充质转化(EMT)。定量地说,EMT与间质成纤维细胞群的激活和扩张相结合,是肾小管萎缩和进行性肾纤维化的主要因素。在体外,EMT由多种细胞因子和环境因素驱动;然而,我们假设肾脏EMT是由三种主要转录网络驱动的亚稳态:tgf - β /Smad;E -钙粘蛋白/β-连环蛋白/ Wnt / LEF / TCF;MAPK/ERK信号级联。我们已经确定了MMP-2和MT1-MMP作为MAPK/ERK信号级联的转录靶点,并确定了特定的AP-1复合物成分Fra-2足以驱动体外EMT过程。该建议的主要假设是,持续的MAPK/ERK信号传导,以及增强的Fra-2的产生,驱动肾脏EMT所需的一系列特定基因的转录。解决这一问题的方法包括三个特定目标,即使用微阵列分析来表征一系列上皮细胞克隆群体中显示一系列上皮到间质特征的fr -2调节基因。所鉴定基因的功能意义将通过体外和体内方法进行验证,包括通过在肾近端小管中转基因表达活性MMP-2产生的肾脏EMT的独特模型。最后,将通过转基因近端小管表达该转录因子来测试fr -2单独在体内诱导EMT的能力。这些研究旨在确定肾脏EMT所需的基因集,从而有望为肾脏疾病的治疗提供新的治疗靶点。
英文摘要
DESCRIPTION (provided by applicant): Interstitial fibrosis and tubular atrophy are the hallmarks of all forms of progressive renal fibrosis. This laboratory has focused over the past decade on the role of specific (MMP-2 and MT1-MMP) in this process. MMP-2, in conjunction with MT1-MMP, is sufficient to induce the conversion of the polarized epithelial cell to a fibroblastic phenotype, a process termed epithelial mesenchymal transition (EMT). Quantitatively, EMT, in conjunction with activation and expansion of the interstitial fibroblast population, is a major contributor to tubular atrophy and progressive renal fibrosis. In vitro, EMT is driven by a diverse number of cytokines and environmental factors; however, we have postulated that renal EMT represents a metastable state driven by three dominant transcriptional networks: TGF-beta/Smad; E- cadherin/beta-catenin/Wnt/LEF/TCF; and MAPK/ERK signaling cascades. We have identified both MMP-2 and MT1-MMP as transcriptional targets of the MAPK/ERK signaling cascades and determined that a specific AP-1 complex component, Fra-2, is sufficient to drive the process of EMT in vitro. The primary hypothesis of this proposal is that sustained MAPK/ERK signaling, with enhanced generation of Fra-2, drives the transcription of a defined cohort of genes required for renal EMT. The approaches to this problem include three Specific Aims proposing to characterize, using microarray analysis, Fra-2-regulated genes in a series of clonal populations of epithelial cells displaying a range of epithelial to mesenchymal features. The functional significance of identified genes will be validated using in vitro and in vivo approaches, including a unique model of renal EMT generated by the transgenic expression of active MMP-2 in the renal proximal tubule. Finally, the ability of Fra-2, alone, to induce EMT in vivo will be tested by the transgenic proximal tubule expression of this transcription factor. These studies are designed to identify those gene sets required for renal EMT and thereby hopefully provide new therapeutic targets for the treatment of renal disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
-
批准号:8195892
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:DAVID H LOVETT
-
依托单位:
Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
-
批准号:7797295
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:DAVID H LOVETT
-
依托单位:
Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
-
批准号:7904116
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:DAVID H LOVETT
-
依托单位:
Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury
-
批准号:8597347
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2009
-
负责人:DAVID H LOVETT
-
依托单位:
Pathobiology of Renal Matrix Metabolism
-
批准号:7031422
-
项目类别:
-
资助金额:$8.25万
-
财政年份:2005
-
负责人:DAVID H LOVETT
-
依托单位:
Matrix metalloproteinase-2 & progressive cardiac fibrosi
-
批准号:6652376
-
项目类别:
-
资助金额:$30.87万
-
财政年份:2002
-
负责人:DAVID H LOVETT
-
依托单位:
Pathology of Renal Matrix Metabolism
-
批准号:6327467
-
项目类别:
-
资助金额:$33.15万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
Pathology of Renal Matrix Metabolism
-
批准号:6517147
-
项目类别:
-
资助金额:$34.14万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
PATHOBIOLOGY OF GLOMERULAR MATRIX METABOLISM
-
批准号:3239741
-
项目类别:
-
资助金额:$17.64万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
GROWTH FACTORS AND MESANGIAL MATRIX METABOLISM
-
批准号:3239740
-
项目类别:
-
资助金额:$17.2万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
PATHOBIOLOGY OF GLOMERULAR MATRIX METABOLISM
-
批准号:2141057
-
项目类别:
-
资助金额:$6.36万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
GROWTH FACTORS AND MESANGIAL MATRIX METABOLISM
-
批准号:3239737
-
项目类别:
-
资助金额:$16.2万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
PATHOLOGY OF GLOMERULAR MATRIX METABOLISM
-
批准号:2391407
-
项目类别:
-
资助金额:$26.72万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
PATHOLOGY OF GLOMERULAR MATRIX METABOLISM
-
批准号:6177031
-
项目类别:
-
资助金额:$29.1万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
PATHOLOGY OF GLOMERULAR MATRIX METABOLISM
-
批准号:2684182
-
项目类别:
-
资助金额:$27.48万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
Pathology of Renal Matrix Metabolism
-
批准号:6729193
-
项目类别:
-
资助金额:$40.11万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
PATHOBIOLOGY OF GLOMERULAR MATRIX METABOLISM
-
批准号:3239743
-
项目类别:
-
资助金额:$19.09万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
Pathology of Renal Matrix Metabolism
-
批准号:7541736
-
项目类别:
-
资助金额:$32.19万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
PATHOBIOLOGY OF GLOMERULAR MATRIX METABOLISM
-
批准号:3239738
-
项目类别:
-
资助金额:$17.95万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
Pathology of Renal Matrix Metabolism
-
批准号:7030705
-
项目类别:
-
资助金额:$33.83万
-
财政年份:1987
-
负责人:DAVID H LOVETT
-
依托单位:
国内基金
海外基金
多模态超声VisTran-Attention网络评估早期子宫颈癌保留生育功能手术可行性
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:郑巧
-
依托单位:
Ultrasomics-Attention孪生网络早期精准评估肝内胆管癌免疫治疗的研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈立达
-
依托单位: